Related references
Note: Only part of the references are listed.Risk disclosure and preclinical Alzheimer's disease clinical trial enrollment
Joshua D. Grill et al.
ALZHEIMERS & DEMENTIA (2013)
Regulatory Innovation and Drug Development for Early-Stage Alzheimer's Disease
Nicholas Kozauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study
Eric M. Reiman et al.
LANCET NEUROLOGY (2012)
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
Randall J. Bateman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Reisa A. Sperling et al.
ALZHEIMERS & DEMENTIA (2011)
Face-name associative memory performance is related to amyloid burden in normal elderly
Dorene M. Rentz et al.
NEUROPSYCHOLOGIA (2011)
Testing the Right Target and Right Drug at the Right Stage
Reisa A. Sperling et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Individual differences in spatial pattern separation performance associated with healthy aging in humans
Shauna M. Stark et al.
LEARNING & MEMORY (2010)
Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease
Ellen Grober et al.
JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY (2008)
Share Paper
